Fjarde Ap Fonden Alnylam Pharmaceuticals, Inc. Transaction History

Fjarde Ap Fonden

$11.6 Billion
Q3 2025

A detailed history of Fjarde Ap Fonden transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Fjarde Ap Fonden holds 30,215 shares of ALNY stock, worth $14.5 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares

30,215

Previous 30,015 0.67%

Holding current value

$14.5 Million

Previous $9.79 Million 40.76%

% of portfolio

0.12%

Previous 0.09%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 28, 2025	BUY	$311.12 - $482.13 $62,224 - $96,426	200 Added 0.67%	30,215 $13.8 Million
Q2 2025 Aug 01, 2025	BUY	$224.32 - $326.09 $695,392 - $1.01 Million	3,100 Added 11.52%	30,015 $9.79 Million
Q1 2025 May 13, 2025	SELL	$233.07 - $290.7 $512,754 - $639,540	-2,200 Reduced 7.56%	26,915 $7.27 Million
Q4 2024 Feb 04, 2025	BUY	$232.27 - $300.43 $301,951 - $390,559	1,300 Added 4.67%	29,115 $6.85 Million
Q3 2024 Nov 08, 2024	BUY	$233.81 - $287.01 $93,524 - $114,804	400 Added 1.46%	27,815 $7.65 Million
Q1 2024 Apr 25, 2024	SELL	$146.51 - $198.2 $73,255 - $99,100	-500 Reduced 1.79%	27,415 $4.1 Million
Q4 2023 Feb 14, 2024	SELL	$151.41 - $196.57 $75,705 - $98,285	-500 Reduced 1.76%	27,915 $5.34 Million
Q3 2023 Oct 23, 2023	SELL	$170.77 - $211.65 $17,077 - $21,165	-100 Reduced 0.35%	28,415 $5.03 Million
Q2 2023 Aug 02, 2023	SELL	$185.01 - $212.05 $259,014 - $296,870	-1,400 Reduced 4.68%	28,515 $5.42 Million
Q1 2023 May 15, 2023	BUY	$182.66 - $235.53 $182,660 - $235,530	1,000 Added 3.46%	29,915 $5.99 Million
Q4 2022 Feb 14, 2023	SELL	$185.53 - $241.31 $333,954 - $434,358	-1,800 Reduced 5.86%	28,915 $6.87 Million
Q2 2022 Aug 11, 2022	SELL	$120.42 - $169.29 $710,478 - $998,811	-5,900 Reduced 16.11%	30,715 $4.48 Million
Q1 2022 May 13, 2022	SELL	$127.18 - $173.91 $419,694 - $573,903	-3,300 Reduced 8.27%	36,615 $5.98 Million
Q4 2021 Feb 15, 2022	SELL	$159.56 - $209.29 $154,613 - $202,802	-969 Reduced 2.37%	39,915 $6.77 Million
Q3 2021 Nov 15, 2021	SELL	$169.75 - $207.73 $135,800 - $166,184	-800 Reduced 1.92%	40,884 $7.72 Million
Q2 2021 Aug 12, 2021	BUY	$128.63 - $176.89 $128,630 - $176,890	1,000 Added 2.46%	41,684 $7.07 Million
Q1 2021 May 17, 2021	BUY	$126.83 - $175.69 $202,928 - $281,104	1,600 Added 4.09%	40,684 $5.74 Million
Q4 2020 Feb 12, 2021	SELL	$122.97 - $147.0 $282,831 - $338,100	-2,300 Reduced 5.56%	39,084 $5.08 Million
Q3 2020 Nov 13, 2020	BUY	$121.19 - $165.49 $302,975 - $413,725	2,500 Added 6.43%	41,384 $6.03 Million
Q2 2020 Aug 13, 2020	SELL	$104.21 - $156.44 $135,473 - $203,372	-1,300 Reduced 3.24%	38,884 $5.76 Million
Q1 2020 May 11, 2020	BUY	$93.12 - $133.99 $307,296 - $442,167	3,300 Added 8.95%	40,184 $4.37 Million
Q4 2019 Feb 10, 2020	BUY	$74.51 - $124.23 $439,609 - $732,957	5,900 Added 19.04%	36,884 $4.25 Million
Q3 2019 Oct 31, 2019	BUY	$70.9 - $87.82 $517,570 - $641,086	7,300 Added 30.82%	30,984 $2.49 Million
Q2 2019 Jul 17, 2019	SELL	$65.86 - $92.79 $335,886 - $473,229	-5,100 Reduced 17.72%	23,684 $1.72 Million
Q1 2019 Apr 29, 2019	BUY	$72.76 - $93.45 $257,352 - $330,532	3,537 Added 14.01%	28,784 $2.69 Million
Q4 2018 Jan 31, 2019	SELL	$62.67 - $88.33 $213,078 - $300,322	-3,400 Reduced 11.87%	25,247 $1.84 Million
Q3 2018 Nov 09, 2018	SELL	$87.52 - $122.67 $89,708 - $125,736	-1,025 Reduced 3.45%	28,647 $2.51 Million
Q2 2018 Jul 12, 2018	BUY	$88.31 - $107.8 $131,316 - $160,298	1,487 Added 5.28%	29,672 $2.92 Million
Q1 2018 May 07, 2018	SELL	$115.92 - $148.54 $127,512 - $163,394	-1,100 Reduced 3.76%	28,185 $3.36 Million
Q4 2017 Feb 12, 2018	BUY	$114.49 - $139.98 $3.35 Million - $4.1 Million	29,285	29,285 $3.72 Million

Others Institutions Holding ALNY

# of Institutions

803

Shares Held

116M

Call Options Held

584K

Put Options Held

648K

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $58.9B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fjarde Ap Fonden , based on Form 13F filings with the SEC.

News

Stay updated on Fjarde Ap Fonden with notifications on news.

Account